» Articles » PMID: 31958799

Upregulation of MiR-552 Predicts Unfavorable Prognosis of Gastric Cancer and Promotes the Proliferation, Migration, and Invasion of Gastric Cancer Cells

Overview
Journal Oncol Res Treat
Specialty Oncology
Date 2020 Jan 21
PMID 31958799
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Accumulating evidence indicates that micro-RNAs play a key role in tumor progression and prognosis. However, the overall biological role and clinical significance of microRNA-552 (miR-552) in the pathogenesis of gastric cancer (GC) remain unclear.

Methods: miR-552 expression was measured in 122 pairs of cancerous and noncancerous tissues and cell lines by quantitative real-time polymerase chain reaction. The relationship between miR-552 and the clinical parameters of patients was analyzed by the χ2 test; Kaplan-Meier analysis and multivariate Cox regression analysis were used to predict the overall survival time and prognosis of patients with different expression of miR-552. Finally, CCK-8 and Transwell were used to detect the changes in cell proliferation, migration, and invasion ability.

Results: miR-552 was expressed at markedly high levels in GC tissues compared to normal tissues and in some GC cell lines (p < 0.001). The upregulation of miR-552 was significantly associated with tumors with advanced TNM stage (p = 0.026), lymph node metastasis (p = 0.018), intestinal metaplasia (p = 0.044), and genomically stable subtype (p = 0.035). Moreover, GC patients with high miR-552 expression showed shorter overall survival (log-rank test, p = 0.011) than those with low expression. Meanwhile, miR-552 was an independent prognostic factor for GC patients (HR 5.657, 95% CI 1.619-19.761, p = 0.007). Finally, miR-552 overexpression promoted the proliferation, migration, and invasion of GC cells (p < 0.01).

Conclusion: Taken together, our results indicate that miR-552, as an oncogene of GC, can promote cell proliferation, migration, and invasion, and miR-552 may be a novel prognostic biomarker for GC.

Citing Articles

PLASMA: Partial LeAst Squares for Multiomics Analysis.

Yamaguchi K, Abdelbaky S, Yu L, Oakes C, Abruzzo L, Coombes K Cancers (Basel). 2025; 17(2).

PMID: 39858069 PMC: 11763701. DOI: 10.3390/cancers17020287.


The role of microRNAs in the gastric cancer tumor microenvironment.

Yu X, Zhang Y, Luo F, Zhou Q, Zhu L Mol Cancer. 2024; 23(1):170.

PMID: 39164671 PMC: 11334576. DOI: 10.1186/s12943-024-02084-x.


High-throughput sequencing analysis of differential microRNA expression in the process of blocking the progression of chronic atrophic gastritis to gastric cancer by Xianglian Huazhuo formula.

Yuxi G, Ze L, Nan C, Xuemei J, Jie W, Hongyu M J Tradit Chin Med. 2024; 44(4):703-712.

PMID: 39066531 PMC: 11337255. DOI: 10.19852/j.cnki.jtcm.20240617.002.


In Pursuit of Novel Markers: Unraveling the Potential of miR-106, CEA and CA 19-9 in Gastric Adenocarcinoma Diagnosis and Staging.

Boicean A, Boeras I, Birsan S, Ichim C, Todor S, Onisor D Int J Mol Sci. 2024; 25(14).

PMID: 39063140 PMC: 11277351. DOI: 10.3390/ijms25147898.


Regulation of the PD-1/PD-L1 Axis and NK Cell Dysfunction by Exosomal miR-552-5p in Gastric Cancer.

Tang C, Yang J, Qin J, Wu H, Cui H, Ge L Dig Dis Sci. 2024; 69(9):3276-3289.

PMID: 39020183 PMC: 11415408. DOI: 10.1007/s10620-024-08536-0.